Major Depressive Disorder Program
Major Depressive Disorder (MDD)
Phase 3Active
Key Facts
About Actipulse Neuroscience
Actipulse Neuroscience is a clinical-stage neurotech company developing novel non-invasive brain stimulation devices for central nervous system disorders. Backed by Y Combinator and operating as a Paris Brain Institute company, it leverages a proprietary platform of high-frequency magnetic pulse technology. Its lead program for Major Depressive Disorder is in Phase 3, with a preclinical pipeline targeting oncology and other CNS conditions. The company aims to become the gold standard in neuromodulation within five years.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| Deep TMS (H1 Coil) | BrainsWay | FDA Cleared |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| NeuroStar Advanced Therapy | Neuronetics | FDA Cleared |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| BrightKaire Platform for Depression | NeuroKaire | Pre-clinical |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |